-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: The rapid emergence of novel coronavirus volatile organic compounds worldwide is associated with varying levels of resistance to neutralization in convalescent plasma, neutralizing monoclonal antibodies, and post-vaccination serum
Background: The rapid emergence of novel coronavirus volatile organic compounds worldwide is associated with varying levels of resistance to neutralization in convalescent plasma, neutralizing monoclonal antibodies, and post-vaccination serum
During the evaluation of the SARS-COV-2 vaccine, pregnant and breastfeeding women were not included in some large-scale clinical trials
In the current study, we performed a longitudinal quantitative and qualitative analysis of mRNA vaccine-induced antibody responses in postpartum lactating versus non-postpartum lactating women to identify any potential differences in RBD-binding antibodies and neutralize cross-nCoV variability body effectiveness
Methods: We elucidate the antibody profile induced by longitudinal mRNA vaccination in 13 postpartum and 13 non-postpartum women (control group)
RESULTS: Antibody neutralization titers against the 2019-nCoV WA-1 strain were comparable in postpartum and non-postpartum women, and in both groups, these levels persisted up to 4 months after the second vaccination
Figure 1 Antibody titers against various novel coronavirus strains in plasma or breast milk following vaccination in neutralizing postpartum and non-postpartum women
Figure 1 Antibody titers against various novel coronavirus strains in plasma or breast milk following vaccination in neutralizing postpartum and non-postpartum women
Figure 2 Binding antibodies to the vaccine-cognate 2019-nCoV receptor binding domain and its mutants in plasma or breast milk after mRNA vaccination of postpartum and non-postpartum women
Figure 2 Binding antibodies to the vaccine-cognate 2019-nCoV receptor binding domain and its mutants in plasma or breast milk after mRNA vaccination of postpartum and non-postpartum women
Figure 3
Figure 3
Conclusions: This study demonstrates that postpartum women experience different vaccination-induced immune responses compared to non-postpartum women, which may help inform future vaccination strategies in these groups
Original source: Lee Y, Grubbs G, Ramelli SC, et al.
SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women .
EBioMedicine 2022 Mar;77 SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women